project id: TCGA-BLCA; case submitter id: TCGA-YF-AA3M; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.38; rna integrity number: 9.8; age at index: 57; days to birth: -21097; ethnicity: hispanic or latino; gender: male; race: not reported; vital status: Alive; year of birth: 1956; age at diagnosis: 21097; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage II; ajcc pathologic t: T2a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 415.0; icd 10 code: C67.2; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: Yes; progression or recurrence: not reported; site of resection or biopsy: Lateral wall of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Lateral wall of bladder; tumor grade: Not Reported; year of diagnosis: 2013; alcohol history: Not Reported; cigarettes per day: 3.1780821917808217; pack years smoked: 58.0; is ffpe: false; composition: Not Reported; days to collection: 133; days to sample procurement: 0; initial weight: 360.0; portion submitter id: TCGA-YF-AA3M-01A-11; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 5.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0;